LexaGene Holdings Inc (CVE:LXG) (OTCQB:LXXGF) announced Monday another milestone in its journey to commercially launch flagship analyzer
product MiQLab before the end of September – the hiring of LaunchWorks as its contract manufacturer.
LaunchWorks is an FDA registered, ISO 13485 certified, cGMP compliant group specializing in manufacturing consumables for life science firms, LexaGene said.
READ: LexaGene Holdings hires first wave of experienced sales executives ahead of MiQLab launch
It will manufacture the assay panels and buffer sets used in LexaGene’s fully automated MiQLab system.
“LaunchWorks can currently manufacture enough products to easily support our commercial launch and have the facilities to scale their production to meet
any demands that we require. I am very impressed by their facilities, high caliber staff, and their ability to scale their operations to meet our needs as we
grow,” Dr Jack Regan, LexaGene’s CEO and founder, told investors in a statement.
MiQLab is a fully automated genetic analyzer designed to deliver reference-quality data at the point-of-need and can return results in about one hour. LexaGene says the technology can be used in multiple billion-dollar markets, including human and veterinary diagnostics as well as food safety testing.
“This is an extremely exciting time for LexaGene. Our initial hires in sales are working out exceedingly well and we are in the home stretch for manufacturing
and qualification. By the end of next month, we expect to begin selling and fulfilling delivery of our first units, which will be a huge milestone for the company,” added Daryl Rebeck, LexaGene’s president and co-founder.
